Compositions and methods for treating schizophrenia
The disclosure provides a novel polymorph of Compound (I): 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I).HCl.2H 2 O. Pharmaceutical compositions comprising Form (A) of Compound (I).HCl.2H 2 O and related methods of treatment are also disclosed.
1. A pharmaceutical formulation comprising about 10-75 mg of Compound (I)
wherein the formulation is in a sustained-release form suitable for oral administration and comprises a release modifier that provides a maximum plasma concentration (Cmax) of Compound (I) below 30 ng/mL when a dose of 32 mg of Compound (I) is administered to a human.
2. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation has a release rate of 16-24 hours.
3. The pharmaceutical formulation of claim 1 , which comprises a hypromellose.
4. The pharmaceutical formulation of claim 1 , which is in the form of a tablet or capsule.
5. The pharmaceutical formulation of claim 4 , which is a tablet and comprises a hypromellose, a filler, a glidant, and a lubricant.
6. The pharmaceutical formulation of claim 5 , wherein the filler is microcrystalline cellulose, lactose, or a combination thereof.
7. The pharmaceutical formulation of claim 5 , wherein the hypromellose is selected from the group consisting of hypromellose K100LV CR, hypromellose K4M CR, hypromellose E50, or a combination thereof.
8. The pharmaceutical formulation of claim 7 , which comprises 32 mg of Compound (I), 30.0 mg of hypromellose K100LV CR, and 72.0 mg of hypromellose K4M CR.
9. The pharmaceutical formulation of claim 1 , which comprises Compound (I) in an amount of 16 mg, 32 mg, 40 mg, or 64 mg.
10. The pharmaceutical formulation of claim 1 , wherein the formulation provides an AUC of Compound (I) below 350 hr*ng/mL when a dose of 32 mg of Compound (I) is administered to a human.
11. A method of treating or diminishing at least one symptom of schizophrenia in a human subject in need thereof, comprising administering to the subject once daily a pharmaceutical formulation in a sustained-release form suitable for oral administration and comprising 10-75 mg of Compound (I)
wherein the pharmaceutical formulation comprises a release modifier that provides a maximum plasma concentration (Cmax) of Compound (I) below 30 ng/mL when a dose of 32 mg of Compound (I) is administered to a human.
12. The method of claim 11 , wherein the symptom of schizophrenia is a negative symptom of schizophrenia, cognitive impairment, or an aspect of sleep disturbance associated with schizophrenia.
13. The method of claim 11 , wherein the symptom of schizophrenia is cognitive impairment.
14. The method of claim 11 , wherein the formulation comprises between 15-75 mg of Compound (I).
15. The method of claim 14 , wherein the formulation comprises 16 mg, 32 mg, 40 mg, or 64 mg of Compound (I).
16. The method of claim 11 , wherein the release modifier comprises a hypromellose and substantially all of the administered dose of Compound (I) is released from the pharmaceutical formulation over 16-24 hours.
17. The method of claim 16 , wherein the formulation comprises 32 mg of Compound (I).
18. The method of claim 16 , wherein the formulation comprises 64 mg of Compound (I).
19. The method of claim 11 , wherein the formulation is administered in combination with an atypical antipsychotic.
20. The method of claim 19 , wherein the antipsychotic is fluphenazine, risperidone, olanzapine, clozapine, quetiapine, ziprasidone, aripriprazole, seritindole, zotepine, or perospirone.
21. The method of claim 11 , wherein the symptom of schizophrenia is an aspect of sleep disturbance associated with schizophrenia.
22. The method of claim 11 , wherein the symptom of schizophrenia is a negative symptom of schizophrenia.
23. A pharmaceutical formulation comprising about 12-90 mg of the dihydrate hydrochloride salt of Compound (I)
wherein the formulation is in a sustained-release form suitable for oral administration and comprises a release modifier that provides a maximum plasma concentration (Cmax) of Compound (I) below 30 ng/mL when a dose of 38.4 mg of the dihydrate hydrochloride salt of Compound (I) is administered to a human.
24. The pharmaceutical formulation of claim 23 , wherein the pharmaceutical formulation has a release rate of 16-24 hours.
25. The pharmaceutical formulation of claim 23 , which comprises a hypromellose.
26. The pharmaceutical formulation of claim 23 , which is in the form of a tablet or capsule.
27. The pharmaceutical formulation of claim 26 , which is a tablet and comprises a hypromellose, a filler, a glidant, and a lubricant.
28. The pharmaceutical formulation of claim 27 , wherein the filler is microcrystalline cellulose, lactose, or a combination thereof.
29. The pharmaceutical formulation of claim 27 , wherein the hypromellose is selected from the group consisting of hypromellose K100LV CR, hypromellose K4M CR, hypromellose E50, or a combination thereof.
30. The pharmaceutical formulation of claim 29 , which comprises 19.2, 38.4, 48 or 76.8 mg of the dihydrate hydrochloride salt of Compound (I).
31. A method of treating or diminishing at least one symptom of schizophrenia in a human subject in need thereof, comprising administering to the subject once daily the pharmaceutical formulation of claim 23 .
32. The method of claim 31 , wherein the symptom of schizophrenia is a negative symptom of schizophrenia, cognitive impairment, or an aspect of sleep disturbance associated with schizophrenia.
33. The method of claim 31 , wherein the formulation is administered in combination with an atypical antipsychotic.
34. The method of claim 33 , wherein the antipsychotic is fluphenazine, risperidone, olanzapine, clozapine, quetiapine, ziprasidone, aripriprazole, seritindole, zotepine, or perospirone.